Disagreement over the scope of discovery in the multidistrict litigation against the makers of Tylenol prompted lawyers to suggest an off-the-record conference with the judge to prime him on the scientific and regulatory background of the case.
About 30 suits alleging that Tylenol caused liver damage or failure were consolidated earlier this year in the Eastern District of Pennsylvania and 16 similar cases are pending in state court in New Jersey.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
